Loading
A phase 2 trial of gemcitabine + nab-paclitaxel and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC is a phase 2, interventional study registered as NCT07043270 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 35 participants, started 2025-09-29 and due to reach its primary completion in 2028-07-01. Interventions recorded: Nab-paclitaxel + Gemcitabine; modified FOLFIRINOX (mFOLFIRINOX). Conditions listed: Pancreas Adenocarcinoma. Primary outcome: One-year event-free survival (1y-EFS). Pancreatic eligibility wording from the registry: "2024 Pancreatic Adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Gemcitabine + nab-paclitaxel, FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.